CENZESTOTUG
UNII ZZ9BQY81L0

Substance Identification & Data

This profile provides standardized clinical and technical data for Cenzestotug, uniquely identified by the FDA Unique Ingredient Identifier (UNII) ZZ9BQY81L0.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3014361-58-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

ZZ9BQY81L0

CAS Registry Number

3014361-58-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CENZESTOTUG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C176871

National Cancer Institute reference terminology for clinical and research data.

INN ID

13466

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-37

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cenzestotug. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CENZESTOTUG

Common Names & Synonyms

CENZESTOTUG [INN]

CENZESTOTUG [USAN]

H-GAMMA1 HEAVY CHAIN (1-443) (VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV2-2*01 (80.4%) -(IGHD) -IGHJ4*01 (91.7%) S123>L (108)/HOMO SAPIENS IGHV3-30-5*03 (76.5%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT (8.7.7) (26-33.51-57.96-102)) (1-113) -HOMO SAPIENS IGHG1*03V (100%) G1M3>G1M17, NG1M1 CH1 K120, CH3 E12, M14 (CH1 R120>K (210) (114-211), HINGE 1-15 (212-226), CH2 (227-336), CH3 E12 (352), M14 (354) (337-441), CHS (442-443)) (114-443)), (216-214')-DISULFIDE WITH L-KAPPA LIGHT CHAIN (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-33*01 (87.4%) -IGKJ4*01 (81.8%) V124>L (104'), I126>V (106'), CDR-IMGT (6.3.9) (27'-32'.50'-52'.89'-97')) (1'-107') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')); DIMER (222-222'':225-225'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

IMMUNOGLOBULIN G1, ANTI-(HUMAN/MACACA MULATTA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 4) (HUMAN-MUS MUSCULUS MONOCLONAL YH002 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL YH002 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TNFRSF4 (TUMOR NECROSIS FACTOR RECEPTOR (TNFR) SUPERFAMILY MEMBER 4, OX40, CD134)), MONOCLONAL ANTIBODY